DGX.N Hits 20-Day High on Board Appointment News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 Nov 25
Source: Fool
Shares of DGX.N reached a 20-day high today, reflecting positive investor sentiment following Oracle Corporation's announcement of Stephen Rusckowski's election to its Board of Directors. The stock's upward momentum indicates a bullish trend, as investors anticipate the strategic insights Rusckowski, a former CEO of Quest Diagnostics, will bring to Oracle Health. His extensive background in healthcare and technology is expected to enhance Oracle's capabilities in serving patients and healthcare providers. This development, coupled with a broader market rally, has contributed to DGX's strong performance in recent trading sessions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 203.75 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 182.350
Low
190.00
Averages
203.75
High
215.00
Current: 182.350
Low
190.00
Averages
203.75
High
215.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
